A strategic collaboration with Jiangsu Hengrui Pharmaceuticals and EMD Serono

EMD Serono posted on LinkedIn.

“News: Today we entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. This agreement aims to strengthen our robust internal oncology pipeline in DNA damage response (DDR) inhibition and antibody-drug conjugates (ADC) to deliver on our ambition to advance therapeutic options for patients with difficult-to-treat cancers. Learn more here.”

Source: EMD Serono/LinkedIn